Novartis dodges Gilenya kickback claims—again—after whistleblower lawsuit dismissed

For the second time in as many years, Novartis has dodged claims it paid doctors kickbacks at “sham” speaker programs to boost prescriptions of its multiple sclerosis blockbuster Gilenya.